Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

FDA Touts 3D Printing’s Potential in Personalized Medicine

3D Printing MedicalWashington, DC, July 15, 2016 — Christine Ayala reports in The Hill that the Food and Drug Administration (FDA) touted the potential of 3D-printed medical devices and drugs Thursday, releasing regulatory science research on devices already cleared and approved by the agency.

The FDA issued draft guidance on 3D-printed devices in May, which is currently open for comment until Aug. 8.

James Coburn, the principal investigator for the FDA’s Center for Devices and Radiological Health, highlighted the potential for advancements in personalized medicine through 3D printing, also called additive manufacturing.

“With patient-specific devices, there are a lot of areas where people have been thinking about doing this, but it’s been cost prohibitive or technologically prohibitive, and 3D printing has opened up a lot of those doors,” Coburn said.

The FDA has already cleared 85 medical devices and one prescription drug manufactured via 3D printing. The devices, including orthopedic implants and surgical instruments, were approved through the agency’s current oversight of medical devices and drugs.

The FDA calls the guidance its “initial thoughts” on best practices for manufacturing, designing or testing 3D-printed devices, but officials note the rules stop short of addressing products that involve biological material.